SLNO תחזית צמיחת רווחים לשנה הבאה soleno.life

Soleno Therapeutics (SLNO) aims for leadership in the Prader-Willi syndrome therapy niche, supported by strong research positions. However, long-term success depends on FDA approval and the commercialization of the DCCR drug. A potential exit from the development stage is only possible through acquisition by a tech giant. The consensus estimate for net profit growth rates reflects a search for market equilibrium, with the value holding at 73.20.
SLNO (Soleno Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator reflects the consensus forecast for profit growth rates in the coming period by measuring the difference between current and expected EPS. By analyzing the forward net income trend with a value of 73.20, an investor assesses market expectations for the monetization of DCCR by Soleno Therapeutics (SLNO), where monopoly pricing power amid inelastic demand for the Prader-Willi syndrome treatment will serve as the primary growth driver.